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Background: MiRNAs play important roles in diverse biological processes including tumorigenesis. However, little is
known about the function and mechanism of miR-451 in nasopharyngeal carcinoma (NPC).
Methods: Quantitative RT-PCR was used to quantify miR-451 expression in NPC cell lines and clinical tissues.
Kaplan-Meier curves were used to estimate the association between miR-451 expression and survival. The MTT,
colony formation, Transwell migration and invasion assays, and a xenograft model were performed. A miR-451
target was confirmed using luciferase reporter assays, quantitative RT-PCR, and Western blotting.
Results: MiR-451 was significantly downregulated in NPC cell lines and clinical tissues (P < 0.01). Patients with low
expression of miR-451 had poorer overall survival (HR, 1.98; 95% CI, 1.16-3.34; P = 0.01) and disease-free survival (HR,
1.68; 95% CI, 1.07-2.62; P = 0.02) than patients with high expression. MiR-451 was an independent prognostic factor
in NPC in multivariate Cox regression analysis. Ectopic expression of miR-451 suppressed cell viability, colony
formation, and cell migration and invasion in vitro, and inhibited xenograft tumor growth in vivo. MIF was verified
as a direct target of miR-451, and MIF regulated NPC cell growth and invasion.
Conclusions: The newly identified miR-451/MIF pathway provides insight into NPC initiation and progression, and
may represent a novel therapeutic target.
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Nasopharyngeal carcinoma (NPC) is a common head and
neck cancer derived from epithelium cells located in the
nasopharynx. The global statistics by world region revealed
its extremely unbalanced endemic distribution, with the
highest incidence in Southern China [1]. Although ad-
vances made in clinical treatment, the prognosis of NPC
patients, especially with advanced disease, is still very poor
due to the recurrence and distant metastasis [2]. Genetic
susceptibility, Epstein-Barr virus infection, and environ-
mental factors have been reported to be the major etiologic
factors of NPC [3]. Up to date, the accurate molecular* Correspondence: majun2@mail.sysu.edu.cn
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reproduction in any medium, provided the ormechanism underlying the pathogenesis and progression
of NPC is still not fully understood. Therefore, a better
understanding of the molecular mechanism involved in
NPC progression is essential for the development of
novel therapeutic strategies for NPC patients.
MicroRNAs (miRNAs) are small non-coding RNA mole-
cules about 19–25 nucleotide, which exist in many organ-
isms and regulate gene expression at the post-transcriptional
level by base pairing with the 3′-untranslated region
(3′-UTR) of their target genes [4-6]. Generally, a miRNA
can regulate multiple target genes and one gene may be
regulated by multiple miRNAs, underscoring the forma-
tion of complex regulatory networks [4]. It has been
reported that miRNAs can control a variety of biological
processes including cellular differentiation, proliferation,
and apoptosis [7-9]. Recent evidence also indicated
that miRNAs may function as tumor suppressors orThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Liu et al. Molecular Cancer 2013, 12:123 Page 2 of 8
http://www.molecular-cancer.com/content/12/1/123oncogenes, and play critical roles in carcinogenesis [10-12].
Inhibiting or reconstituting special miRNA may have
therapeutic implication and makes them candidates for
therapeutic targets [13-16]. Antagomirs are a type of
antisense oligonucleotide that can effectively inhibit
miRNAs function in vivo [13,14]. Dysregulated expres-
sion of miRNAs has been reported in most tumor
types [17-20], including NPC [21-23]. Recent studies
also reported that several dysregulated miRNAs in-
volved in NPC development and progression by regu-
lating cell growth, proliferation, apoptosis, invasion,
and metastasis [24-27], indicating that miRNAs play im-
portant roles in NPC tumorigenesis. In our recent micro-
array study, we found that miR-451 was downregulated in
NPC [23], however, no study has elucidated the functions
and mechanisms of miR-451 in NPC development and
progression.
In this study, we investigated the prognostic value and
potential roles of miR-451 in NPC. We demonstrated
that miR-451 was downregulated in NPC cell lines and
tissue samples. We further explored its effects on cell
growth, colony formation, invasive, and tumorigenesis.
Moreover, macrophage migration inhibitory factor (MIF)
was identified as a functional target of miR-451. The
newly identified miR-451/MIF pathway elucidated the
roles of miRNAs in the development of NPC and would
provide a novel therapeutic strategy for NPC.Results
MiR-451 is downregulated in NPC cell lines and clinical
specimens
In this study, we firstly tested miR-451 expression in
NPC cell lines and the normal nasopharyngeal epithelial
cell line NP69, and found it was significantly decreased
in NPC cell lines (Figure 1A). We also detected miR-451
expression in 20 freshly-frozen NPC and 8 normalFigure 1 MiR-451 is downregulated in NPC cell lines and clinical samp
(B) Relative expression of miR-29c in NPC (n = 20) and normal nasophary
Data is presented as the mean ± SD, and P values were calculated with tnasopharyngeal epithelial tissue samples and found that
the miR-451 expression was significantly downregulated
in NPC tissues (Figure 1B, P < 0.01).Downregulation of miR-451 is associated with worse
survival in NPC
To evaluate the clinical significance of miR-451, we
detected miR-451 expression in a cohort of 280 paraffin-
embedded NPC biopsy samples using quantitative RT-
PCR. Patients with low expression of miR-451 were found
to have significantly worse overall survival (HR, 1.98; 95%
CI, 1.16-3.34; P = 0.01) and disease-free survival (HR, 1.68;
95% CI, 1.07-2.62; P = 0.02) than those with high expres-
sion (Figure 2). However, no significant correlations were
found between miR-451 expression and any clinical char-
acteristics (Table 1). In addition, multivariate Cox regres-
sion analysis showed that miR-451 expression and clinical
stage were both independent prognostic indicators for
overall survival (HR, 2.00; 95% CI, 1.18-3.41; P = 0.01; HR,
2.93; 95% CI, 1.44-5.97; P < 0.01) and disease-free survival
(HR, 1.81; 95% CI, 1.16-2.83; P = 0.01; HR, 2.41; 95% CI,
1.37-4.23; P < 0.01).MiR-451 suppresses NPC cell viability and colony
formation in vitro
To explore whether ectopic expression of miR-451 af-
fects cell viability and proliferation ability, MTT assay
and colony formation assay were performed after transi-
ent transfection with miR-451 mimics or miR controls
in SUNE-1 and CNE-2 cells. Cells transfected with miR-
451 mimics showed a significant inhibition of growth
compared with those transfected with miR controls
(Figure 3A, P < 0.01). Moreover, cells transfection with
miR-451 mimics displayed much fewer and smaller
colonies compared with controls (Figure 3B, P < 0.01).les. (A) Relative expression of miR-451 in NP69 and NPC cell lines.
ngeal epithelial tissues (n = 8). U6 used as the endogenous control.
he Student’s t-test.
Figure 2 Downregulation of miR-451 is associated with worse survival in NPC patients. (A) Overall survival. (B) Disease-free survival. HR,
hazard ratio, and CI, confidence interval; HR values were calculated with the unadjusted Cox regression analysis, and P values were calculated
with the log-rank test.
Table 1 Associations between miR-451 expression and
clinical characteristics in patients with nasopharyngeal
carcinoma
Characteristics No. of patients Expression of miR-451 P value
Low, n (%) High, n (%)
Age
≤ 45 yr 136 66 (47) 70 (50) 0.63
> 45 yr 144 74 (53) 70 (50)
Sex
Male 206 100 (71) 106 (76) 0.42
Female 74 40 (29) 34 (24)
WHO Type
I + II 11 4 (3) 7 (5) 0.36
III 269 136 (97) 133 (95)
VCA-IgA
< 1:80 43 21 (15) 22 (16) 0.87
≥ 1:80 237 119 (85) 118 (84)
EA-IgA
< 1:10 71 37 (26) 34 (24) 0.68
≥ 1:10 209 103 (74) 106 (76)
T Stage
T1-T2 142 70 (50) 72 (51) 0.81
T3-T4 138 70 (50) 68 (49)
N Stage
N0 42 89 (64) 85 (61) 0.62
N1-N3 238 51 (36) 55 (39)
TNM Stage
I-II 91 49 (35) 42 (30) 0.37
III-IV 189 91 (65) 98 (70)
VCA-IgA: viral capsid antigen immunoglobulin A; EA-IgA: early antigen
immunoglobulin A. All patients were restaged according to the 7th edition of
the AJCC Cancer Staging Manual.
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in vitro
To determine whether ectopic expression of miR-451 has
a biological affect on the cell migration and invasive abil-
ity, SUNE-1 and CNE-2 cells were transiently transfected
with miR-451 mimics or miR controls. Transwell migra-
tion assay demonstrated that the migration ability of cells
transfected with miR-451 mimics was much lower than
those transfected with miR controls (Figure 3C, P < 0.01).
Transwell invasion assay also showed that transfection of
miR-451 mimics significantly reduced the invasive ability
(Figure 3D, P < 0.01).
MiR-451 suppresses NPC xenograft tumor growth in vivo
To further explore whether ectopic expression of miR-
451 affects tumor growth in vivo, we conducted xeno-
grafts tumor model assay by subcutaneously injecting
SUNE-1 cells stably overexpressing miR-451 or scram-
bled miRNA in the dorsal flank of nude mice. We found
that the tumors in the group injected with SUNE-1
cells stably overexpressing miR-451 grew at a slower
rate and had smaller volumes than the scrambled con-
trol (Figure 4A-B, P < 0.01). The average tumor weight
was also significantly lower in the miR-451 overexpressing
group (0.31 ± 0.11 g vs. 0.83 ± 0.26 g; Figure 4C-D,
P < 0.01).
MIF is a direct target of miR-451 and involved in NPC cell
growth and invasion
To address the molecular mechanism by which miR-451
suppressed NPC cell growth and invasion, we identified
MIF as a potential target of miR-451 using two pub-
licly available databases (TargetScan and DIANA). We
constructed luciferase reporter vectors that contained
wild-type or mutant miR-451 target sequences of the
MIF 3′ UTR (Figure 5A), and performed luciferase re-
porter assay to determine whether MIF was a direct
Figure 3 miR-451 suppresses NPC cell viability, colony formation, migration and invasion. (A) MTT assay was performed to test cell
viability of SUNE-1 and CNE-2 cells. (B-D) Representative results of colony formation (B), migration (C), and invasive ability (D) of SUNE-1 and
CNE-2 cells transfected with miR-29c mimics or miR control. Data is presented as the mean ± SD. *, P < 0.01 compared with control using the
Student’s t-test.
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miR-451 inhibited the luciferase activity of the wild-type
3′ UTR reporter gene but not the mutant reporter gene
(Figure 5B, P < 0.01), indicating that miR-451 can bind to
the 3′ UTR of MIF. Furthermore, we found that ectopic
expression of miR-451 could suppress the mRNA and
protein expression of MIF (Figure 5C-D, P < 0.01). Finally,
to determine whether MIF could regulate cell growth andFigure 4 miR-451 suppresses NPC xenograft tumor growth in vivo. (A
subcutaneously injected into nude mice. Four weeks later, SUNE-1 cells sta
growth curves of tumor volumes. (C) Representative picture of tumors form
compared with control using the Student’s t-test.invasion, we transiently transfected SUNE-1 and CNE-2
cells with siMIF or siRNA controls, and found that siMIF
reduced the colonies formation and suppressed invasive
ability (Figure 5E-F, P < 0.01).
Discussion
In this study, we found that miR-451 was downregulated
in NPC cell lines and clinical samples, and downregulation) SUNE-1 cells stably overexpressing miR-451 or scrambled miRNA was
bly overexpressing miR-451 had smaller tumors than controls. (B) The
ed. (D) Tumor weight. Data is presented as the mean ± SD. *, P < 0.01
Figure 5 TIAM1 is a direct target of miR-29c and involved in NPC cell growth and invasion. (A) Wild-type or mutant miR-451 target
sequences of MIF 3′ UTR. (B) Relative luciferase activity of SUNE-1 and CNE-2 cells after co-transfection with wild type (Wt) or mutant (Mt) MIF
3′ UTR reporter genes and miR-29c mimics or control. (C, D) Quantification of MIF mRNA (C) and protein (D) expression after transfection
with miR-451 mimics or control. (E, F) Colony formation (E) and invasive ability (F) after transfection with siMIF or control. Data is presented
as the mean ± SD. *, P < 0.01 compared with control using the Student’s t-test.
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with NPC. Ectopic expression of miR-451 suppressed
NPC cell growth and invasion in vitro and inhibited tumor
growth in vivo. Furthermore, MIF was verified as a direct
target of miR-451, and involved in NPC cell growth and
invasion. Our results suggest that the downregulation of
miR-451 has important roles in the development and pro-
gression of NPC.
Recently, miRNAs have been shown to be important
in maintenance of normal cellular function, and the
dysregulation of miRNAs expression can result in cancer
initiation and tumor progression [7,10,11]. Several stud-
ies reported that miRNAs were dysregulated in NPC
[21-23], and the dysregulated miRNAs could regulate
NPC cell growth, proliferation, and metastasis [24-27].
In our recent microarray study, we found that miR-451
was significantly reduced in NPC. However, little is
known about the function and mechanism of miR-451
involving in NPC development and progression. Our results
further demonstrated that miR-451 was downregulated in
NPC cell lines and freshly-frozen tissue samples. Strikingly,
we found that the downregulation of miR-451 wassignificantly associated with worse survival in patients
with NPC. Multivariate Cox regression analysis further
demonstrated that low expression of miR-451 was an
independent prognostic indicator for NPC patients.
These results indicated that miR-451 could be a useful
prognostic biomarker to stratify NPC patients into dif-
ferent risk groups and further guide the personalized
therapy for NPC patients.
MiR-451 was reported to be frequently downregulated
in several types of tumors [28], such as gastric cancer
[29], lung cancer [30], glioma [31,32], and breast cancer
[32]. Moreover, the dysregulation of miR-451 expression
was involved in the carcinogenesis and progression by
affecting the tumor cellular function, including cell pro-
liferation and growth, cell-cycle distribution, migration,
and invasion [29-31]. In this study, to better understand-
ing the function of miR-451 in NPC, we firstly detected
the effect of miR-451 on cell viability and colony forma-
tion using MTT assay and colony formation assay. The
results showed that ectopic expression of miR-451 could
significantly suppress the cell viability and colony forma-
tion ability. Furthermore, the Transwell migration and
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strated that ectopic expression of miR-451 could inhibit
the cell migration and invasive ability. We also found
that ectopic miR-451 inhibited the xenograft tumor
growth in vivo. Taking together, these results suggested
that the regulation of miR-451 on cell growth and inva-
sion may contribute the development and progression of
NPC.
Each miRNA has the potential to target hundreds of
genes that harbor target sequence in their 3′ UTR com-
plementary to the seed region of the miRNA [4]. Several
targets of miR-451, such as calcium binding protein 39
(CAB39) [32], ras-related protein 14 (RAB14) [30], and
14-3-3§ [33], have been identified. In our present report,
we verified MIF as a direct target of miR-451 using lucif-
erase reporter gene assay, which was consistent with the
finding in gastric cancer [29]. Furthermore, ectopic ex-
pression of miR-451 could significantly reduce the MIF
expression at both the mRMA and protein levels. Several
studies have reported that the expression of MIF was
upregulated in malignant tumors [34], and correlated
with its aggressiveness and metastatic potential by pro-
moting cell growth and invasion [35,36]. Studies also
demonstrated that increasing expression of MIF protein
was associated with poor prognosis in NPC patients
[37,38]. In this study, we found that siMIF could signifi-
cantly inhibit the colonies formation and invasive ability
of NPC cells. These findings suggested that miR-451
suppressed the cell growth and invasion by targeting
MIF.
Conclusions
In conclusion, this report found that downregulation of
miR-451 was associated with worse survival in patients
with NPC, and ectopic expression of miR-451 could sup-
press cell growth and invasion by directly targeting MIF.
This newly identified miR-451/MIF pathway provides
new insight into the molecular mechanisms which regu-
late NPC progression, and further provides novel thera-
peutic strategies for NPC patients.
Materials and methods
Clinical specimens and cell culture
A total of 280 paraffin-embedded NPC specimens were
obtained from Sun Yat-sen University Cancer Center be-
tween January 2003 and February 2006. Twenty freshly-
frozen NPC samples and eight normal nasopharyngeal
epithelium samples were also collected from our center.
No patients had received any anti-tumor treatments be-
fore biopsy. The clinical staging was reclassified according
to the 7th edition of the AJCC Cancer Staging Manual. All
patients were treated with conventional two-dimensional
radiotherapy and 151 (79.9%) of 189 patients with ad-
vanced disease (T3-T4 or N2-N3) also received platinum-based induction or concomitant chemotherapy. The clin-
ical characteristics of NPC patients were listed in Table 1.
The median follow-up time was 63.9 months (range: 3.7-
91.87). Written informed consent was obtained from each
patient for the use of their biopsy samples, and the re-
search protocols were approved by the Academic Com-
mittee of Sun Yat-sen University Cancer Center of our
hospital.
The human immortalized nasopharyngeal epithelial
cell line NP69 was maintained in Keratinocyte/serum-
free medium (Invitrogen) supplemented with bovine pi-
tuitary extract (BD Biosciences), human NPC cell lines
(CNE-1, CNE-2, C666-1, HNE-1, HONE-1, SUNE-1, 5-8 F,
and 6-10B) were cultured in RPMI-1640 (Invitrogen)
supplemented with 10% FBS (Gibco), and 293FT cells
were grown in DMEM (Invitrogen) supplemented with
10% FBS.
RNA extraction, reverse transcription, and real-time
RT-PCR
Total RNA was extracted from paraffin-embedded sam-
ples with acid phenol-Chloroform method [39], and from
freshly-frozen samples with TRIzol reagent (Invitrogen).
Total RNA was reverse-transcribed with M-MLV reverse
transcriptase (Promega) and Bulge-Loop™ miRNA spe-
cific RT-primers (RiboBio) for miR-451 or random
primers (Promega) for MIF. Real time PCR reactions
were conducted using Platinum SYBR Green qPCR
SuperMix-UDG reagents (Invitrogen) on the PRISM
7900HT system (Applied Biosystems). All reactions were
done in triplicate and reactions without reverse transcript-
ase were used as negative controls. The U6 or GAPDH
were used as the endogenous controls for miR-451 orMIF
and the 2-ΔΔCT equation was used to calculate the relative
expression levels [40].
Oligonucleotide transfection and generation of stably
transfected cell lines
Cells were seeded into 6-well plates, transfected with
miR-451 mimics or miR controls (50 nM, GenePharma)
using Lipofactamine™ RNAiMAX (Invitrogen) and
transfected with siMIF (100 nM, Invitrogen) or siRNA
controls using Lipofactamine 2000 reagent (Invitrogen),
and then harvested for assays 48 h later. The lentiviral
plasmid pEZX-MR03 (GeneCopoeia) expressing miR-451
(Cat, HmiR0274-MR03) or scrambled miRNA (Cat,
CmiR0001-MR03) and Lenti-Pac HIV Expression Pack-
aging mix (GeneCopoeia) were cotransfected into 293FT
cells using EndoFectin Lenti transfection reagent
(GeneCopoeia). After transfection for 48 h, lentiviral
particles were harvested and then transduced into the
SUNE-1 cells, and the stably transfected cells were
selected using puromycin and validated by real time
RT-PCR.
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SUNE-1 and CNE-2 cells were seeded at 1500 cells per
well in 96-well plates after transfection. MTT assay was
performed to test cell viability at 1, 2, 3, 4, and 5 days,
and the absorbance was measured at 490 nm with a
spectrophotometric plate reader. For colony formation
assay, SUNE-1 and CNE-2 cells were plated at 500 cells
per well in six-well plates after transfection, and cultured
for 12 days. Colonies were fixed with methanol/acetic
acid (3:1, v/v), stained with 0.5% crystal violet, and counted
under the inverted microscope.
In vitro migration and invasion assay
Transwell chambers (Corning) were coated without or
with Matrigel (BD Biosciences) on the upper surface of
membrane with 8 μm pore size, and used to test the cell
migration or invasive ability. Briefly, 5 × 104 or 1 × 105
SUNE-1 and CNE-2 cells suspended in serum-free media
were plated into the upper chamber for migration or inva-
sion assay after transfection, and media supplemented
with 10% FBS was placed into the lower chamber. After
incubation for 8 h or 24 h, the cells that had migrated or
invaded through the membrane to the lower surface were
fixed, stained, and counted under the inverted microscope
(100×).
In vivo tumor growth model
Male BALB/c nude mice aged 4 to 6 weeks were pur-
chased from the Hunan Slac Jingda Laboratory Animal
Co., Ltd (Changsha, China). For tumor growth assay,
SUNE-1 cells stably overexpression miR-451 or scramble
miRNA were resuspended in PBS and 1 × 106 cells
(200 μl) were subcutaneously injected in the dorsal flank
of nude mice. Tumor size was measured every 3 days
and tumor volumes were calculated with the following
formula: volume = (L ×W2)/2, in which L meant the lon-
gest diameter and W meant the shortest diameter. Four
weeks later, mice were sacrificed, and tumors were dis-
sected and weighted. Animal handling and research pro-
tocols were approved by the Animal Care and Use
Ethnic Committee.
Luciferase reporter assay
The MIF wild-type (Wt) and mutant (Mt) 3′ UTR were
created and cloned to the firefly luciferase-expressing
vector psiCHECK™ (Promega). For the luciferase assay,
SUNE-1 and CNE-2 cells were seeded in 6-well plates
the day before transfection, and cotransfected with the
MIF Wt or Mt 3′UTR reporter vector, the control
vector pRL-TK (Promega), and miR-451 mimics or
negative-control (NC) using Lipofectamine 2000 (Invitrogen).
Luciferase activities were determined with the Dual-
Luciferase Reporter System (Promega).Western blotting
Total cell proteins were separated using 9% SDS-PAGE
gels, and transferred to PVDF (polyvinylidene fluoride)
membranes (Millipore). Then, the membranes were in-
cubated with mouse monoclonal anti-MIF antibody
(1:1000; Abcam) followed by incubation with the HRP
(horseradish peroxidase)-labeled goat anti-mouse IgG
(1:2000; Boster). Bands were detected with chemilumin-
escence, and an anti-α-tubulin antibody (1:1000, Sigma)
was used as the loading control.
Statistical analysis
Data were presented as mean ± SD. The Student’s t-test,
Chi-square test or Fisher’s exact test were used for com-
parisons between groups. The Kaplan-Meier method was
used to estimate overall survival and disease-free survival,
and multivariate Cox regression analysis with backward
stepwise approach was used to test for independent prog-
nostic factors. All statistical analysis was performed with
SPSS 16.0 software, and P values of < 0.05 were defined as
statistically significant.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NL, NJ, RG, WJ, QH, YX, and YL performed experiments; JM, NL, NJ, WJ, QH,
YX, YL, LT, and YS designed research, analyzed data and edited the
manuscript for intellectual content. All authors have made critical edits to
the manuscript and have given final approval.
Acknowledgments
This work was supported by grants from Guangdong Province Universities
and Colleges Pearl River Scholar Funded Scheme (2011, 2050205), the
National Natural Science Foundation of China (Nos. 81071835, 81101695,
81201746), the Innovation Team Development Plan of the Ministry of
Education (No. IRT1297), the Science and Technology Project of Guangzhou
City (No. 12C22061586), and the Guangdong Natural Science Foundation
(No. S2012010009658). The funders had no role in the study design, data
collection, analysis, decision to publish or the preparation of the manuscript.
Received: 31 July 2013 Accepted: 10 October 2013
Published: 20 October 2013
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61:69–90.
2. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ, Ma J:
How does intensity-modulated radiotherapy versus conventional two-
dimensional radiotherapy influence the treatment results in
nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys 2011,
80:661–668.
3. McDermott AL, Dutt SN, Watkinson JC: The aetiology of nasopharyngeal
carcinoma. Clin Otolaryngol Allied Sci 2001, 26:82–92.
4. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 2004, 116:281–297.
5. He L, Hannon GJ: MicroRNAs: small RNAs with a big role in gene
regulation. Nat Rev Genet 2004, 5:522–531.
6. Zamore PD, Haley B: Ribo-gnome: the big world of small RNAs. Science
2005, 309:1519–1524.
7. Ambros V: The functions of animal microRNAs. Nature 2004, 431:350–355.
8. Ambros V: MicroRNA pathways in flies and worms: growth, death, fat,
stress, and timing. Cell 2003, 113:673–676.
Liu et al. Molecular Cancer 2013, 12:123 Page 8 of 8
http://www.molecular-cancer.com/content/12/1/1239. Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM: Bantam encodes a
developmentally regulated microRNA that controls cell proliferation and
regulates the proapoptotic gene hid in drosophila. Cell 2003, 113:25–36.
10. Calin GA, Croce CM: MicroRNA-cancer connection: the beginning of a
new tale. Cancer Res 2006, 66:7390–7394.
11. Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer.
Nat Rev Cancer 2006, 6:259–269.
12. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S,
Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM: A
microRNA polycistron as a potential human oncogene. Nature 2005,
435:828–833.
13. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M,
Stoffel M: Silencing of microRNAs in vivo with ‘antagomirs’. Nature
2005, 438:685–689.
14. Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A,
Hedtjarn M, Hansen JB, Hansen HF, Straarup EM, McCullagh K, Kearney P,
Kauppinen S: Antagonism of microRNA-122 in mice by systemically
administered LNA-antimiR leads to up-regulation of a large set of
predicted target mRNAs in the liver. Nucleic Acids Res 2008, 36:1153–1162.
15. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, Fu C,
Lindow M, Stenvang J, Straarup EM, Hansen HF, Koch T, Pappin D,
Hannon GJ, Kauppinen S: Silencing of microRNA families by seed-
targeting tiny LNAs. Nat Genet 2011, 43:371–378.
16. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, Lindholm M,
Hedtjarn M, Hansen HF, Berger U, Gullans S, Kearnery P, Sarnow P, Straarup EM,
Kauppinen S: LNA-mediated microRNA silencing in non-human primates.
Nature 2008, 452:896–899.
17. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev
Cancer 2006, 6:857–866.
18. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A,
Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR:
MicroRNA expression profiles classify human cancers. Nature 2005,
435:834–838.
19. Liu C, Iqbal J, Teruya-Feldstein J, Shen Y, Dabrowska MJ, Dybkaer K, Lim MS,
Piva R, Barreca A, Pellegrino E, Spaccarotella E, Lachel CM, Kucuk C, Jiang CS,
Hu X, Bhaqavathi S, Greiner TC, Weisenburger DD, Aoun P, Perkins SL,
McKeithan TW, Inghirami G, Chan WC: MicroRNA expression profiling
identifies molecular signatures assocaited with anapastic large cell
lymphoma. Blood 2013, 122:2083–2092.
20. Cho WC: MicroRNA in cancer – from research to therapy. Biochim Biophys
Acta 1805, 2010:209–217.
21. Chen HC, Chen GH, Chen YH, Liao WL, Liu CY, Chang KP, Chang YS, Chen SJ:
MicroRNA deregulation and pathway alterations in nasopharyngeal
carcinoma. Br J Cancer 2009, 100:1002–1011.
22. Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ,
Chen CJ, Hildesheim A, Sugden B, Ahlquist P: MicroRNA 29c is down-
regulated in nasopharyngeal carcinomas, up-regulating mRNAs
encoding extracellular matrix proteins. Proc Natl Acad Sci U S A 2008,
105:5874–5878.
23. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ,
Chen M, He QM, Jiang N, Chen L, Cho WC, Yun JP, Zeng J, Liu LZ, Li L,
Guo Y, Wang HY, Ma J: Prognostic value of a microRNA signature in
nasopharyngeal carcinoma: a microRNA expression analysis. Lancet
Oncol 2012, 13:633–641.
24. Liu N, Tang LL, Sun Y, Cui RX, Wang HY, Huang BJ, He QM, Jiang W, Ma J:
MiR-29c suppresses invasion and metastasis by targeting TIAM1 in
nasopharyngeal carcinoma. Cancer Lett 2013, 329:181–188.
25. Yi C, Wang Q, Wang L, Huang Y, Li L, Liu L, Zhou X, Xie G, Kang T, Wang H,
Zeng M, Ma J, Zeng Y, Yun JP: MiR-663, a microRNA targeting p21 (WAF1/
CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal
carcinoma. Oncogene 2012, 31:4421–4433.
26. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT,
Kung HF, Li XP: MiR-26a inhibits cell growth and tumorigenesis of
nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011,
71:225–233.
27. Xia H, Cheung WK, Sze J, Lu G, Jiang S, Yao H, Bian XW, Poon WS, Kung HF,
Lin MC: miR-200a regulates epithelial-mesenchymal to stem-like
transition via ZEB2 and beta-catenin signaling. J Biol Chem 2010,
285:36995–37004.
28. Pan X, Wang R, Wang ZX: The potential role of miR-451 in cancer
diagnosis, prognosis, and therapy. Mol Cancer Ther 2013, 12:1153–1162.29. Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, Zarate R, Diaz-
Gonzalez JA, Ramirez N, Sola JJ, Jimenez P, Rodriguez J, Garcia-Foncillas J:
microRNA-451 regulates macrophage migration inhibitory factor
production and proliferation of gastrointestinal cancer cells. Clin Cancer
Res 2009, 15:2281–2290.
30. Wang R, Wang ZX, Yang JS, Pan X, De W, Chen LB: MicroRNA-451
functions as a tumor suppressor in human non-small cell lung cancer by
targeting ras-related protein 14 (RAB14). Oncogene 2011, 30:2644–2658.
31. Godlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler S: microRNA-451: A
conditional switch controlling glioma cell proliferation and migration.
Cell Cycle 2010, 9:2742–2748.
32. Tian Y, Nan Y, Han L, Zhang A, Wang G, Jia Z, Hao J, Pu P, Zhong Y, Kang C:
MicroRNA miR-451 downregulates the PI3K/AKT pathway through
CAB39 in human glioma. Int J Oncol 2012, 40:1105–1112.
33. Bergamaschi A, Katzenellenbogen BS: Tamoxifen downregulation of miR-
451 increases 14-3-3zeta and promotes breast cancer cell survival and
endocrine resistance. Oncogene 2012, 31:39–47.
34. Ren Y, Law S, Huang X, Lee PY, Bacher M, Srivastava G, Wong J:
Macrophage migration inhibitory factor stimulates angiogenic factor
expression and correlates with differentiation and lymph node status in
patients with esophageal squamous cell carcinoma. Ann Surg 2005,
242:55–63.
35. Meyer-Siegler KL, Leifheit EC, Vera PL: Inhibition of macrophage migration
inhibitory factor decreases proliferation and cytokine expression in
bladder cancer cells. BMC Cancer 2004, 4:34.
36. Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR:
Ovarian cancer cell-derived migration inhibitory factor enhances
tumor growth, progression, and angiogenesis. Mol Cancer Ther 2007,
6:1993–2002.
37. Li J, Mo HY, Xiong G, Zhang L, He J, Huang ZF, Liu ZW, Chen QY, Du ZM,
Zheng LM, Qian CN, Zeng YX: Tumor microenvironment macrophage
inhibitory factor directs the accumulation of interleukin-17-producing
tumor-infiltrating lymphocytes and predicts favorable survival in
nasopharyngeal carcinoma patients. J Biol Chem 2012, 287:35484–35495.
38. Liao B, Zhong BL, Li Z, Tian XY, Li Y, Li B: Macrophage migration inhibitory
factor contributes angiogenesis by up-regulating IL-8 and correlates
with poor prognosis of patients with primary nasopharyngeal
carcinoma. J Surg Oncol 2010, 102:844–851.
39. Korbler T, Grskovic M, Dominis M, Antica M: A simple method for RNA
isolation from formalin-fixed and paraffin-embedded lymphatic tissues.
Exp Mol Pathol 2003, 74:336–340.
40. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods
2001, 25:402–408.
doi:10.1186/1476-4598-12-123
Cite this article as: Liu et al.: MiR-451 inhibits cell growth and invasion
by targeting MIF and is associated with survival in nasopharyngeal
carcinoma. Molecular Cancer 2013 12:123.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
